Dupilumab biosimilar (Qilu Pharma)

度普利尤单抗生物类似药（齐鲁制药）

Report date: 2025/10/30 14:36:33

Base Information

Drug NameDupilumab biosimilar (Qilu Pharma)
Drug Alias NameQL2108QL-2108
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-13 inhibitorsInterleukin-4 inhibitorsInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-13Interleukin-4Interleukin-4 receptor subunit alpha
Therapy Area/IndicationsPrurigoDermatitis, AtopicAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPrurigoDermatitis, AtopicAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A